Gilead, Cognizant
Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...
The stock's fall snapped a two-day winning streak.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.
J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback